



# SUVEN Life Sciences Ltd

Communication to investors  
December 2016



# Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



# FINANCIAL QUICK VIEW

	FY 2016-17 Q3 to Q2	FY 2016-17 YoY 9 months
Growth in revenue	-1.51%	9.98%
Growth in PAT	-8.65%	32.77%
Growth in EBIDTA	-4.29%	38.90%
Growth in Pre-R&D EBIDTA	-0.28%	25.94%
Increase in R&D Costs	11.64%	-1.01%
R&D to sales	13.58%	12.01%

# MAJOR PROFITABILITY RATIOS







	Q3 Dec 16	9 months- Dec 16
PAT to Income	20.06%	21.83%
EBIDTA to Income	34.67%	35.04%
Cash Flow to Income	24.19%	25.66%
Pre-R&D EBITDA to Income	48.25%	47.05%



# Q3 to Q2 COMPARISON


Current quarter to previous quarter





# REVENUE COMPARISON

Year on year




1-Feb-17

2016-17 Q3 results



# PAT COMPARISON

Year on year




1-Feb-17

2016-17 Q3 results



# EBIDTA COMPARISON

Year on year



1-Feb-17


2016-17 Q3 results





# R & D – EXPENDITURE


Year on year





# PRE-R&D EBIDTA

Year on year




1-Feb-17

2016-17 Q3 results



# PRE-R&D CASHFLOW

Year on year



1-Feb-17

2016-17 Q3 results



# FINANCIAL SNAPSHOT

All figures are in INR Million, other than ratios and EPS

	2016-17 Q3	2016-17 Q2	Growth %	2015-16 Q3	Growth %	2016-17 9M Dec16	2015-16 9M Dec15	Growth %
Income	1,204.55	1,223.05	-1.51%	1,167.06	3.21%	3,804.84	3,459.72	9.98%
Pre-R&D EBITDA	581.24	582.90	-0.28%	432.70	34.33%	1,790.35	1,421.56	25.94%
Pre-R&D EBITDA Margin	48.25%	47.66%		37.08%		47.05%	41.09%	
EBITDA	417.64	436.36	-4.29%	281.01	48.62%	1,333.31	959.88	38.90%
EBITDA Margin	34.67%	35.68%		24.08%		35.04%	27.74%	
EBIT	368.92	390.84	-5.61%	235.81	56.45%	1,191.01	840.66	41.68%
EBIT Margin	30.63%	31.96%		20.21%		31.30%	24.30%	
Financing costs	12.65	12.37		16.55		40.98	41.97	
Taxes	113.57	112.89		48.64		316.00	169.67	
Net Profit after tax	241.58	264.44	-8.65%	169.50	42.53%	830.65	625.63	32.77%
NP Margin	20.06%	21.62%		14.52%		21.83%	18.08%	
EPS (basic & diluted not annualised)	1.90	2.08		1.33		6.53	4.92	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28		127.28	127.28	
Depreciation	48.72	45.52		45.20		142.30	119.22	
R&D expenses	163.60	146.54	11.64%	151.70	7.85%	457.03	461.69	-1.01%

# News Release



- During the period Suven secures 5 product patents covering India, Eurasia, Norway, Australia and USA.
- Suven presented at 9<sup>th</sup> Clinical Trials on Alzheimer's Disease (CTAD) conference held in December in San Diego, USA
- Suven, Inc., presented in Biotech Showcase 2017 held in January, 2017 in San Francisco, USA
- Suven, Inc., participated in 35<sup>th</sup> JP Morgan Healthcare Conference held in January, 2017 in San Francisco.
- The Board has proposed an Interim Dividend of Re. 1 per share (100% of face value of Rs. 1.00 each).